Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 3 studies described adult participants.

1 relevant study has unresolved authoritative design evidence and does not contribute to design-specific or RoB-specific claims.

1 supporting study does not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group.

3 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Not extracted from the authoritative source.

Clinician-reference record is usable with limitations in: comparator.

A case of a 27-year-old ex-sumo wrestler with Type 2 Diabetes and morbid obesity receiving dulaglutide.

Dulaglutide Treatment

After introducing dulaglutide, he achieved a 40 kg (−21%) weight loss and a BMI reduction of 10.3 kg/m2 over 6 months, with no side effects and improved glycemic control.

Dulaglutide may improve weight loss in obese patients with diabetes

Source evidence could not be resolved sufficiently for this field.

Available source content was suppressed because validation identified a conflict.

Metformin Group

Clinician-reference record is usable with limitations in: design, risk_of_bias.

Patients received semaglutide as part of their treatment regimen.

Semaglutide Group

Patients received either semaglutide, up to 1 mg subcutaneous (sc) weekly, or dulaglutide, up to 1.5 mg sc weekly, as the standard of care in addition to their usual medication regimen.

Patients received dulaglutide as part of their treatment regimen.

Dulaglutide Group

Patients received metformin as the control treatment.

Twenty subjects with T2DM and obesity were started on metformin and a diet and served as the control group.

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

Authoritative quality diagnostic: source evidence unresolved.

GLP-1 agonists reduce heart fat thickness in diabetes.

Patients received once-weekly dulaglutide 1.5 mg for 52 weeks.

Dulaglutide 1.5 mg

Patients were randomized to once-weekly dulaglutide 1.5 (n = 612), 3.0 (n = 616) or 4.5 mg (n = 614) for 52 weeks.

Patients received once-weekly dulaglutide 3.0 mg for 52 weeks.

Dulaglutide 3.0 mg

Patients received once-weekly dulaglutide 4.5 mg for 52 weeks.

Dulaglutide 4.5 mg

Higher dulaglutide doses improve weight loss in type 2 diabetes

Structured population data were available for 2 of 3 supporting studies. 1 study described participants with type 2 diabetes. 2 studies described adult participants.

2 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

2 supporting studies do not have a displayable topic-matched quantitative effect.

1 supporting study lacks usable structured population information.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 11 of 11 supporting studies. Diabetes type was heterogeneous: 9 studies with type 2 diabetes, 1 studies with type 1 diabetes. 11 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo, usual_care.

9 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.

Structured population data were available for 3 of 3 supporting studies. 3 studies described participants with type 2 diabetes. 2 studies described adult participants.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

2 of 3 studies with duration data have follow-up of 12 weeks or less.

1 study contains conflicting p-value and significance fields; those significance claims are suppressed.

Evidence uses heterogeneous comparison contexts: active_comparator, usual_care.

Structured population data were available for 5 of 5 supporting studies. 3 studies described participants with type 2 diabetes. 5 studies described adult participants.

Structured population data were available for 4 of 4 supporting studies. 2 studies described adult participants.

Evidence uses heterogeneous comparison contexts: baseline_within_group, unknown_unresolved, usual_care.

Structured population data were available for 3 of 3 supporting studies. 1 study described participants with type 2 diabetes. 2 studies described adult participants.

Structured population data were available for 5 of 5 supporting studies. 4 studies described participants with type 2 diabetes. 4 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo.

Evidence uses heterogeneous comparison contexts: unknown_unresolved, usual_care.

Structured population data were available for 9 of 9 supporting studies. 3 studies described participants with type 2 diabetes. 7 studies described adult participants.

Evidence uses heterogeneous comparison contexts: baseline_within_group, other, unknown_unresolved, usual_care.

4 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 4 of 4 supporting studies. 4 studies described participants with type 2 diabetes. 3 studies described adult participants.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, placebo.

Structured population data were available for 3 of 3 supporting studies. 1 study described participants with type 2 diabetes. 3 studies described adult participants.

Upstream consistency scoring indicates mixed findings across the evidence.

Evidence uses heterogeneous comparison contexts: placebo, usual_care.

Evidence uses heterogeneous comparison contexts: active_comparator, unknown_unresolved.

Structured population data were available for 4 of 4 supporting studies. 3 studies described participants with type 2 diabetes. 4 studies described adult participants.

Structured population data were available for 9 of 9 supporting studies. 9 studies described participants with type 2 diabetes. 9 studies described adult participants.

Dulaglutide × BMI

Available supporting studies

Dulaglutide may improve weight loss in obese patients with diabetes

GLP-1 agonists reduce heart fat thickness in diabetes.

Higher dulaglutide doses improve weight loss in type 2 diabetes